CJC-1295 vs Ipamorelin

Evidence-based comparison. Updated 2026.

CJC-1295 and Ipamorelin both stimulate growth hormone release but through different receptor pathways, making them complementary rather than competing options. CJC-1295 suits those prioritizing sustained GH elevation and longer dosing intervals, while Ipamorelin is preferred when minimizing cortisol and prolactin side effects is a priority. For most research contexts, combining both is more effective than using either alone.

Side by side

	CJC-1295	Ipamorelin
Evidence	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data
Regulatory	CompoundableCompoundableLegal to compound in the US, or approved in other jurisdictions or historically	CompoundableCompoundableLegal to compound in the US, or approved in other jurisdictions or historically
Benefits	Increases growth hormone and IGF-1 levels Promotes muscle growth and fat loss Improves recovery and sleep quality Enhances bone density Supports anti-aging processes	Stimulates growth hormone release Minimal effect on cortisol and prolactin Supports lean muscle mass development Aids in fat metabolism and anti-aging Improves sleep quality
Dosage	100-200 mcg (no DAC) or 2 mg (with DAC) mcg, Daily before bed (no DAC) or Once weekly (with DAC)	200-300 mcg mcg, 1-3x daily
Route	Subcutaneous	Subcutaneous
Category	Growth Hormone Secretagogues	Growth Hormone Secretagogues

Full research page

CJC-1295

Full research page

Ipamorelin

Which should you choose

CJC-1295 acts on GHRH receptors to increase GH pulse amplitude, while Ipamorelin acts on ghrelin receptors to trigger selective GH release. These distinct mechanisms target the same outcome through different pathways, which is why they are frequently studied together.

Choose CJC-1295 when

You want sustained elevation of GH and IGF-1 levels over a longer dosing window, particularly with the DAC version.
Your primary research focus is on GH pulse amplitude rather than frequency, which CJC-1295 is better suited to modulate.
Dosing convenience is a priority, as the DAC formulation supports less frequent administration compared to daily peptide protocols.

Choose Ipamorelin when

Minimizing off-target hormonal effects such as cortisol and prolactin elevation is a key research criterion.
You are studying selective GH secretagogue activity with high pituitary specificity and a clean hormonal profile.
The research context involves frequent, controlled GH pulses rather than sustained baseline elevation.

Stacking CJC-1295 with Ipamorelin is a widely documented protocol in peptide research because their complementary receptor mechanisms produce a synergistic increase in GH secretion greater than either peptide achieves alone.

Questions people ask

Does combining CJC-1295 and Ipamorelin produce better results than using either alone?

Research on GH secretagogue combinations suggests that pairing a GHRH analog like CJC-1295 with a ghrelin receptor agonist like Ipamorelin produces a synergistic amplification of GH release. CJC-1295 increases baseline GH pulse amplitude while Ipamorelin triggers selective pulsatile release, and together they engage both regulatory pathways simultaneously. This dual-receptor approach is why the combination is among the most studied GH peptide protocols.

How do the timelines for noticeable effects differ between CJC-1295 and Ipamorelin?

Ipamorelin produces a rapid, short-duration GH pulse following administration, with peak GH levels typically observed within one to two hours. CJC-1295 with DAC, by contrast, produces a slower onset but sustained elevation in GH and IGF-1 levels that can persist for several days due to albumin binding. In combined protocols, Ipamorelin contributes to immediate pulsatile activity while CJC-1295 provides the prolonged hormonal background, meaning observable effects on body composition and recovery may take several weeks of consistent use.

Which peptide carries a higher risk of side effects when comparing CJC-1295 to Ipamorelin?

CJC-1295 carries a moderately higher risk profile due to its sustained GH elevation, which can amplify side effects such as water retention, joint discomfort, and transient insulin resistance if GH levels remain chronically elevated. Ipamorelin is generally considered lower risk because of its selectivity for GH release with minimal impact on cortisol or prolactin. When stacked, the combined protocol requires monitoring for compounded GH-related side effects, though the selective nature of Ipamorelin partially offsets this concern.

Can CJC-1295 and Ipamorelin be used at different dosing frequencies within the same protocol?

Yes, and this is a common feature of combination protocols. Ipamorelin, due to its short half-life, is typically administered daily or multiple times per day to generate frequent GH pulses. CJC-1295 without DAC is also dosed daily, while the DAC version can be dosed once or twice weekly due to its extended half-life from albumin binding. Matching the dosing schedule of CJC-1295 without DAC to Ipamorelin injections is the most straightforward combined protocol in research settings.

Goal-based guides

Broader evidence guides for the goals this comparison relates to.

Best peptides for Muscle Growth

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide